Barclays PLC Has $332,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Barclays PLC increased its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 312.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 240,615 shares of the company’s stock after buying an additional 182,315 shares during the quarter. Barclays PLC owned 0.08% of Lyell Immunopharma worth $332,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LYEL. Bank of New York Mellon Corp lifted its holdings in shares of Lyell Immunopharma by 6.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 671,966 shares of the company’s stock worth $974,000 after acquiring an additional 38,487 shares during the period. American Century Companies Inc. raised its position in Lyell Immunopharma by 18.1% in the second quarter. American Century Companies Inc. now owns 279,425 shares of the company’s stock worth $405,000 after purchasing an additional 42,752 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Lyell Immunopharma by 197.8% during the second quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock worth $58,000 after purchasing an additional 26,635 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Lyell Immunopharma by 14.4% during the second quarter. The Manufacturers Life Insurance Company now owns 553,163 shares of the company’s stock valued at $802,000 after purchasing an additional 69,712 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC grew its stake in shares of Lyell Immunopharma by 49.5% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 128,203 shares of the company’s stock valued at $186,000 after purchasing an additional 42,452 shares during the period. 66.05% of the stock is currently owned by institutional investors.

Lyell Immunopharma Trading Up 3.0 %

NASDAQ LYEL opened at $0.58 on Monday. Lyell Immunopharma, Inc. has a 1-year low of $0.55 and a 1-year high of $3.26. The company has a 50 day moving average of $0.80 and a 200-day moving average of $1.17. The firm has a market cap of $168.14 million, a price-to-earnings ratio of -0.73 and a beta of -0.35.

Lyell Immunopharma (NASDAQ:LYEL) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. The firm had revenue of $0.03 million during the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. On average, analysts forecast that Lyell Immunopharma, Inc. will post -0.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

LYEL has been the subject of several analyst reports. Bank of America downgraded Lyell Immunopharma from a “buy” rating to an “underperform” rating and cut their target price for the stock from $6.00 to $1.00 in a research report on Wednesday, October 30th. HC Wainwright reissued a “neutral” rating and set a $1.00 price objective on shares of Lyell Immunopharma in a report on Tuesday, November 12th.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.